Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameCF Pharmtech
Stock Code02652
Company Full NameCF PharmTech, Inc.
IndustryBiotech & Pharma
Principal Activitiescornerstone of successful inhalation formulations
Listing Date2025-10-08
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)Suzhou Jiangsu PRC Principal Place of Business in 31/F., Tower Two Hong Kong Times Square, 1 Matheson Street Causeway Bay Hong Kong
Business Address (Hong Kong)香港 銅鑼灣 勿地臣街1號時代廣場 二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.cfpharmtech.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar ContactComputershare Hong Kong Investor
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism B
Offer PriceHK$ 14.75 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 7,375
Par ValueRMB 1.0 / shares
Offer Period2025-09-26 to 2025-10-02
Global Offering Shares41,198,000 shares
HK Public Offer Shares (Initial)4,120,000 shares (10.0%)
Public Offer Lots (Initial)8,240lots (Pool A4,120lots,Pool B4,120lots)
International Placing Shares (Initial)37,078,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO411,978,387 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersMechanism B: no clawback
Reallocation OptionNo
Total Global Offering SizeHK$ 607,670,500

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 7,375
2 lots 1,000 HK$ 14,750
3 lots 1,500 HK$ 22,125
4 lots 2,000 HK$ 29,500
5 lots 2,500 HK$ 36,875
6 lots 3,000 HK$ 44,250
7 lots 3,500 HK$ 51,625
8 lots 4,000 HK$ 59,000
9 lots 4,500 HK$ 66,375
10 lots 5,000 HK$ 73,750
12 lots 6,000 HK$ 88,500
14 lots 7,000 HK$ 103,250
16 lots 8,000 HK$ 118,000
18 lots 9,000 HK$ 132,750
20 lots 10,000 HK$ 147,500
30 lots 15,000 HK$ 221,250
40 lots 20,000 HK$ 295,000
50 lots 25,000 HK$ 368,750
60 lots 30,000 HK$ 442,500
70 lots 35,000 HK$ 516,250
80 lots 40,000 HK$ 590,000
90 lots 45,000 HK$ 663,750
100 lots 50,000 HK$ 737,500
120 lots 60,000 HK$ 885,000
140 lots 70,000 HK$ 1,032,500
160 lots 80,000 HK$ 1,180,000
180 lots 90,000 HK$ 1,327,500
200 lots 100,000 HK$ 1,475,000
400 lots 200,000 HK$ 2,950,000
600 lots 300,000 HK$ 4,425,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
800 lots 400,000 HK$ 5,900,000
1,000 lots 500,000 HK$ 7,375,000
1,200 lots 600,000 HK$ 8,850,000
1,400 lots 700,000 HK$ 10,325,000
1,600 lots 800,000 HK$ 11,800,000
1,800 lots 900,000 HK$ 13,275,000
2,000 lots 1,000,000 HK$ 14,750,000
3,000 lots 1,500,000 HK$ 22,125,000
4,120 lots 2,060,000 HK$ 30,385,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 5.71B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 6,076,681,208
H-Share Market Cap (at Offer Price)HK$ 4,457,797,893
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot applicable (loss-making)
Profit/Loss StatusNet profit RMB 21.1 million
Period-End Cash BalanceRMB 81.94 million
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 38.5
First Day OpenHK$ 47.0
First Day Change161.02%
First Day Volume13550700.0
First Day Turnover610929000.0
Use of Proceeds
1、約40.0%或210.2百萬港元將用于為國內及國際的吸入制劑候選產品的持續研發、臨床開發及商業化提供資金; 2、約20.0%或105.1百萬港元將用于為多個管線計劃及技術的臨床前研發提供資金; 3、約30.0%或157.6百萬港元將用于為生產設施、設備采購及生產管理系統的擴張及升級提供資金; 4、約10.0%或52.5百萬港元將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
中信证券(香港)有限公司 CE AAK249 招银国际融资有限公司 CE AVM940
Overall Coordinators (3)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225
Joint Bookrunners (12)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 东吴证券国际经纪有限公司 CE AYA587 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 SPDB International Capital Limited CE BFZ375 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 中州国际证券有限公司 CE BFI947 交银国际证券有限公司 CE APJ121 农银国际证券有限公司 CE ACX411 Guosen Securities (HK) Brokerage Company, Limited CE AUI491
Joint Lead Managers (12)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 东吴证券国际经纪有限公司 CE AYA587 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 SPDB International Capital Limited CE BFZ375 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 中州国际证券有限公司 CE BFI947 交银国际证券有限公司 CE APJ121 农银国际证券有限公司 CE ACX411 Guosen Securities (HK) Brokerage Company, Limited CE AUI491

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman梁文青—
Company Secretary朱玉玉—
No director data available.

Major Shareholders

Major Shareholders & HoldingsDr. Liang holds, through interests in controlled corporations, 30,834,604 unlisted shares (7.5%) and 46,251,905 H shares (11.2%), and jointly holds with Dr. Li Li 9,585,819 unlisted shares (2.3%) and 14,378,728 H shares (3.5%); Dr. Li Li holds, through interests in controlled corporations, 25,743,263 unlisted shares (6.2%) and 38,614,894 H shares (9.4%), and jointly holds with Dr. Liang 14,677,160 unlisted shares (3.6%) and 22,015,739 H shares (5.3%); Advanced Manufacturing Fund holds 26,058,641 H shares (6.3%).
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO attracted staggering demand with an oversubscription ratio of 6697.8x, reflecting extreme market enthusiasm for the biomedical sector. The hit rate of just 3.12% indicates severe allocation scarcity, typical of hot Hong Kong IPOs where retail investors scramble for minimal shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

A notable inefficiency exists between the A-tail and B-head: applying HKD 300,000 yields just 0.0533 expected lots, while HKD 400,000 yields 0.083 lots, offering a minuscule marginal gain of only 0.0297 lots for an extra HKD 100,000. This suggests that the marginal benefit of moving from the top of A-tier to the bottom of B-tier is extremely poor, making lower-tier applications almost as effective. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic data is not available for this IPO, preventing any analysis of mainland China participation, gender, or regional distribution. Without such information, we cannot identify typical patterns like Guangdong dominance or broad cross-border interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows CF Pharmtech (02652) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect